Biotech rivals Kite Pharma (KITE) and Juno Therapeutics (JUNO) were up Tuesday after FBR issued a bullish response to their presentations at the American Society of Hematology (ASH) conference. Analyst Ed White lifted his price target on Kite stock to 72 from 65, though he retained his rating of market perform. He made the change Monday afternoon after Kite released an update on its phase-one trial of its treatment KTE-C19 for diffuse large B-cell
Biotech Bluebird Bio plunged to a 52-week low Monday after the latest data on its gene therapy for severe anemia failed to live up to the promise of earlier data, leading to several downgrades. On Sunday at the annual American Society of Hematology (ASH) conference, Bluebird (BLUE) detailed its early-stage findings on patients with sickle-cell disease (SCD) and beta-thalassemia, two genetic diseases that cause anemia, who were treated with its
One of the biggest medical meetings of the year is this weekend, as the American Society of Hematology (ASH) convenes in Orlando, Fla., to hear about the latest attacks on some of the world’s most intractable blood cancers. Already, some abstracts of presentations released ahead of the conference have made a splash. Tiny French biotech Cellectis (CLLS) will offer details on a case study of an infant with acute lymphoblastic leukemia (ALL) who was